KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Treasury Shares: 2021-2024

Historic Treasury Shares for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Dec 2024 value amounting to $27.3 million.

  • Recursion Pharmaceuticals' Treasury Shares rose 69.35% to $30.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.6 million, marking a year-over-year increase of 69.35%. This contributed to the annual value of $27.3 million for FY2024, which is 79.35% up from last year.
  • Per Recursion Pharmaceuticals' latest filing, its Treasury Shares stood at $27.3 million for FY2024, which was up 79.35% from $15.2 million recorded in FY2023.
  • In the past 5 years, Recursion Pharmaceuticals' Treasury Shares registered a high of $27.3 million during FY2024, and its lowest value of $478,136 during FY2021.
  • Moreover, its 3-year median value for Treasury Shares was $15.2 million (2023), whereas its average is $16.5 million.
  • Data for Recursion Pharmaceuticals' Treasury Shares shows a peak YoY spiked of 1,341.96% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Recursion Pharmaceuticals' Treasury Shares stood at $478,136 in 2021, then soared by 1,341.96% to $6.9 million in 2022, then spiked by 120.81% to $15.2 million in 2023, then skyrocketed by 79.35% to $27.3 million in 2024.